Jorge Sierra describes the clinical benefit of adding drugs that target mutations into treatment regimens and explains the importance of mutational profiling at diagnosis and relapse to determine treatment options. He discusses target therapies that are available to patients, including
- midostaurin (FLT3 inhibitor) for the frontline setting
- ivosidenib (IDH1 inhibitor) for the relapsed/refractory (R/R) setting
- enasidenib (IDH2 inhibitor) for the R/R setting
- gilteritinib (FLT3 inhibitor) for the R/R setting
He concludes by discussing other novel agents that have shown efficacy in the treatment of AML, including venetoclax and gemtuzumab ozogamicin.